

Sales of Main Products by Region

Japan

	¥ billion		
	2015.3	2016.3	2017.3 (Forecast)
Sales in the Japanese market*1	481.7	483.0	456.6
XTANDI	14.9	26.2	25.7
Vesicare	25.6	26.5	27.2
Betanis	14.8	21.2	27.4
Harnal	15.0	12.7	9.4
Prograf	48.1	49.8	47.8
Funguard	11.8	11.7	11.5
Micardis	95.7	97.2	90.8
Micombi	10.7	10.1	
Micamlo	23.8	26.0	
Celecox	41.8	46.6	50.4
Symbicort	33.0	37.4	41.1
Bonoteo	13.0	14.1	15.1
Geninax	10.4	10.8	10.2
Vaccines	38.8	41.1	25.9
ARGAMATE	5.9	6.2	6.1
Kiklin	1.5	1.6	2.0
Gonax	3.4	3.9	4.6
Cimzia	5.0	6.6	9.6
Suglat	4.1	7.3	12.5
Lipitor*2	36.7	30.9	22.4
Myslee	19.4	17.9	14.6
Gaster	18.0	14.7	10.5
Seroquel	12.6	10.5	7.2

Americas

	US\$ million		
	2015.3	2016.3	2017.3 (Forecast)
Sales in the Americas	3,284	3,788	4,011
XTANDI	803	1,272	1,544
US	779	1,235	1,488
Outside of the US	24	37	56
Tarceva	444	389	
US	305	281	
Outside of the US	139	108	
VESIcare	559	530	488
Myrbetriq	254	380	472
Prograf and ASTAGRAF XL	301	288	245
Scan*3	603	634	637
MYCAMINE	112	109	107
AmBisome	82	91	89
CRESEMBA	-	22	45
Protopic*4	94	26	

EMEA

	€ million		
	2015.3	2016.3	2017.3 (Forecast)
Sales in EMEA	2,258	2,484	2,717
XTANDI	241	533	767
Eligard	136	131	138
Vesicare	305	300	259
BETMIGA	74	101	146
Omnice	159	139	127
Sales by Astellas	130	116	109
Bulk and royalties	30	23	18
Prograf and Advagraf	588	609	609
Sales by Astellas	560	588	589
Advagraf	207	234	
Exports to third parties	28	21	20
MYCAMINE	74	85	90
Protopic*4	56	58	
QUTENZA	13	16	
DIFICLIR	14	20	

Asia & Oceania

	¥ billion		
	2015.3	2016.3	2017.3 (Forecast)
Sales in Asia & Oceania	74.2	91.1	88.3
Prograf	32.0	38.4	37.1
Harnal	18.3	21.5	20.5
Vesicare	5.3	5.3	5.4
BETMIGA	0.2	1.4	2.8
MYCAMINE	4.4	5.7	6.0
Protopic*4	3.4	4.6	
XTANDI	0.6	2.4	4.5
Eligard	0.1	0.2	0.3

*1 Sales of products in Japan are shown on a gross sales basis.

*2 Transferred distribution for Caduet to Pfizer Japan Inc. on April 1, 2015. Results for the previous fiscal year represent sales excluding Caduet.

*3 Sales of Adenoscan and Lexiscan

*4 Transferred the global dermatology business, including Protopic, to LEO Pharma A/S on April 1, 2016.